Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice

Biochemical Pharmacology

Volumn 76, Issue 1, 2008, Pages 108-119

  Nakajima, Takero ^a   Tanaka, Naoki ^a,b   Sugiyama, Eiko ^a,c   Kamijo, Yuji ^a,b   Hara, Atsushi ^a   Hu, Rui ^a,d   Li, Gang ^a,e   Li, Yufeng ^a   Nakamura, Kozo ^f   Gonzalez, Frank J ^g   Aoyama, Toshifumi ^a  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Nagano Prefectural College   (Japan)

^d HEBEI MEDICAL UNIVERSITY   (China)

^e HEBEI GENERAL HOSPITAL   (China)

^f SHINSHU UNIVERSITY   (Japan)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bezafibrate; Cholesterol metabolism; Peroxisome proliferator activated receptor (PPAR); Ppara null mice; Sterol regulatory element binding protein (SREBP) 2

Indexed keywords

BEZAFIBRATE; BILE ACID; FARNESOID X RECEPTOR; LIVER X RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ANIMAL EXPERIMENT; ARTICLE; BILE SECRETION; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; LIVER; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BASE SEQUENCE; BEZAFIBRATE; BILE; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CHOLESTEROL; DNA PRIMERS; GENE EXPRESSION; MICE; MICE, KNOCKOUT; PPAR ALPHA; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 45049087998     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.04.001     Document Type: Article

References (57)

1. Schulzeck P., Bojanovski M., Jochim A., Canzler H., and Bojanovski D. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. Lancet 1 (1988) 611-613
2. Pazzucconi F., Mannucci L., Mussoni L., Gianfranceschi G., Maderna P., Werba P., et al. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. Eur J Clin Pharmacol 43 (1992) 219-223
3. Bradford R.H., Goldberg A.C., Schonfeld G., and Knopp R.H. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia. Atherosclerosis 92 (1992) 31-40
4. Roglans N., Bellido A., Rodríguez C., Cabrero A., Novell F., Ros E., et al. Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. Clin Pharmacol Ther 72 (2002) 692-701
5. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
6. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
7. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20 (1999) 649-688
8. Aoyama T., Peters J.M., Iritani N., Nakajima T., Furihata K., Hashimoto T., et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J Biol Chem 273 (1998) 5678-5684
9. Nakajima T., Kamijo Y., Tanaka N., Sugiyama E., Tanaka E., Kiyosawa K., et al. Peroxisome proliferator-activated receptor α protects against alcohol-induced liver damage. Hepatology 40 (2004) 972-980
10. Kamijo Y., Hora K., Nakajima T., Kono K., Takahashi K., Ito Y., et al. Peroxisome proliferator-activated receptor α protects against glomerulonephritis induced by long-term exposure to the plasticizer di-(2-ethylhexyl)phthalate. J Am Soc Nephrol 18 (2007) 176-188
11. Tanaka N., Moriya K., Kiyosawa K., Koike K., Gonzalez F.J., and Aoyama T. PPARα activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 118 (2008) 683-694
12. Hunt M.C., Yang Y.Z., Eggertsen G., Carneheim C.M., Gåfvels M., Einarsson C., et al. The peroxisome proliferator-activated receptor α (PPARα) regulates bile acid biosynthesis. J Biol Chem 275 (2000) 28947-28953
13. Kok T., Bloks V.W., Wolters H., Havinga R., Jansen P.L.M., Staels B., et al. Peroxisome proliferator-activated receptor α (PPARα)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J 369 (2003) 539-547
14. Brown P.J., Winegar D.A., Plunket K.D., Moore L.B., Lewis M.C., Wilson J.G., et al. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARα agonist with potent lipid-lowering activity. J Med Chem 42 (1999) 3785-3788
15. Inoue I., Itoh F., Aoyagi S., Tazawa S., Kusama H., Akahane M., et al. Fibrate and statin synergistically increase the transcriptional activities of PPARα/RXRα and decrease the transactivation of NFκB. Biochem Biophys Res Commun 290 (2002) 131-139
16. Peters J.M., Aoyama T., Burns A.M., and Gonzalez F.J. Bezafibrate is a dual ligand for PPARα and PPARβ: studies using null mice. Biochim Biophys Acta 1632 (2003) 80-89
17. Poirier H., Niot I., Monnot M.C., Braissant O., Meunier-durmort C., Costet P., et al. Differential involvement of peroxisome-proliferator-activated receptors α and δ in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine. Biochem J 355 (2001) 481-488
18. Hays T., Rusyn I., Burns A.M., Kennett M.J., Ward J.M., Gonzalez F.J., et al. Role of peroxisome proliferator-activated receptor-α (PPARα) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26 (2005) 219-227
19. Nagasawa T., Inada Y., Nakano S., Tamura T., Takahashi T., Maruyama K., et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 536 (2006) 182-191
20. Osumi T., Hashimoto T., and Ui N. Purification and properties of acyl-CoA oxidase from rat liver. J Biochem 87 (1980) 1735-1746
21. Miyazawa S., Furuta S., and Hashimoto T. Induction of a novel long-chain acyl-CoA hydrolase in rat liver by administration of peroxisome proliferators. Eur J Biochem 117 (1981) 425-430
22. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., et al. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15 (1995) 3012-3022
23. Usui S., Hara Y., Hosaki S., and Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 43 (2002) 805-814
24. Hara A., and Radin N.S. Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem 90 (1978) 420-426
25. Carr T.P., Andresen C.J., and Rudel L.L. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 26 (1993) 39-42
26. Aoyama T., Uchida Y., Kelley R.I., Marble M., Hofman K., Tonsgard J.H., et al. A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase. Biochem Biophys Res Commun 191 (1993) 1369-1372
27. Aoyama T., Souri M., Ushikubo S., Kamijo T., Yamaguchi S., Kelley R.I., et al. Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients. J Clin Invest 95 (1995) 2465-2473
28. Tanaka N., Moriya K., Kiyosawa K., Koike K., and Aoyama T. Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor α in transgenic mice: implications for HCV-associated hepatocarcinogenesis. Int J Cancer 122 (2008) 124-131
29. Trauner M., and Boyer J.L. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83 (2003) 633-671
30. Mandard S., Müller M., and Kersten S. Peroxisome proliferator-activated receptor α target genes. Cell Mol Life Sci 61 (2004) 393-416
31. Tanaka N., Hora K., Makishima H., Kamijo Y., Kiyosawa K., Gonzalez F.J., et al. In vivo stabilization of nuclear retinoid X receptor α in the presence of peroxisome proliferator-activated receptor α. FEBS Lett 543 (2003) 120-124
32. Lee C.H., Olson P., Hevener A., Mehl I., Chong L.W., Olefsky J.M., et al. PPARδ regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103 (2006) 3444-3449
33. Degenhardt T., Saramäki A., Malinen M., Rieck M., Väisänen S., Huotari A., et al. Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor β/δ. J Mol Biol 372 (2007) 341-355
34. Motojima K., Passilly P., Peters J.M., Gonzalez F.J., and Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. J Biol Chem 273 (1998) 16710-16714
35. Memon R.A., Tecott L.H., Nonogaki K., Beigneux A., Moser A.H., Grunfeld C., et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 141 (2000) 4021-4031
36. Chiang J.Y.L. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 23 (2002) 443-463
37. Kok T., Wolters H., Bloks V.W., Havinga R., Jansen P.L.M., Staels B., et al. Induction of hepatic ABC transporter expression is part of the PPARα-mediated fasting response in the mouse. Gastroenterology 124 (2003) 160-171
38. Mak P.A., Kast-Woelbern H.R., Anisfeld A.M., and Edwards P.A. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J Lipid Res 43 (2002) 2037-2041
39. Moschetta A., Bookout A.L., and Mangelsdorf D.J. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med 10 (2004) 1352-1358
40. Claudel T., Staels B., and Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 25 (2005) 2020-2030
41. Brown M.S., and Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 (1997) 331-340
42. Horton J.D., Goldstein J.L., and Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 (2002) 1125-1131
43. Norlin M., and Chiang J.Y.L. Transcriptional regulation of human oxysterol 7α-hydroxylase by sterol response element binding protein. Biochem Biophys Res Commun 316 (2004) 158-164
44. Matsuda M., Korn B.S., Hammer R.E., Moon Y.A., Komuro R., Horton J.D., et al. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev 15 (2001) 1206-1216
45. Yang J., Goldstein J.L., Hammer R.E., Moon Y.A., Brown M.S., and Horton J.D. Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene. Proc Natl Acad Sci USA 98 (2001) 13607-13612
46. Basso F., Freeman L., Knapper C.L., Remaley A., Stonik J., Neufeld E.B., et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res 44 (2003) 296-302
47. Ragozin S., Niemeier A., Laatsch A., Loeffler B., Merkel M., Beisiegel U., et al. Knockdown of hepatic ABCA1 by RNA interference decreases plasma HDL cholesterol levels and influences postprandial lipemia in mice. Arterioscler Thromb Vasc Biol 25 (2005) 1433-1438
48. Chinetti-Gbaguidi G., Rigamonti E., Helin L., Mutka A.L., Lepore M., Fruchart J.C., et al. Peroxisome proliferator-activated receptor α controls cellular cholesterol trafficking in macrophages. J Lipid Res 46 (2005) 2717-2725
49. Thumser A.E.A., and Wilton D.C. The binding of cholesterol and bile salts to recombinant rat liver fatty acid-binding protein. Biochem J 320 (1996) 729-733
50. Martin G.G., Atshaves B.P., McIntosh A.L., Mackie J.T., Kier A.B., and Schroeder F. Liver fatty-acid-binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. Biochem J 391 (2005) 549-560
51. Kurihara T., Niimi A., Maeda A., Shigemoto M., and Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 95 (2000) 2990-2992
52. Kurihara T., Maeda A., Shigemoto M., Yamashita K., and Hashimoto E. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol 97 (2002) 212-214
53. Kaplan M.M., and Gershwin M.E. Primary biliary cirrhosis. N Engl J Med 353 (2005) 1261-1273
54. Abshagen U., Bablok W., Koch K., Lang P.D., Schmidt H.A.E., Senn M., et al. Disposition pharmacokinetics of bezafibrate in man. Eur J Clin Pharmacol 16 (1979) 31-38
55. Monk J.P., and Todd P.A. Bezafibrate A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 33 (1987) 539-576
56. West K.L., and Fernandez M.L. Guinea pigs as models to study the hypocholesterolemic effects of drugs. Cardiovasc Drug Rev 22 (2004) 55-70
57. Fernandez M.L. Guinea pigs as models for cholesterol and lipoprotein metabolism. J Nutr 131 (2001) 10-20